FDA says the risk will be noted in a labeling change for bisphosphonate medications that treat osteoporosis and in a medication guide for each patient. FDA is still unclear about whether bisphosponates are the cause of the bone breaks.
The agency will continue to evaluate bisphosponates for osteoporosis treatment.
Read the FDA report on bisphosphonates.
Read other coverage on FDA decisions:
– FDA to Revoke OK of Menaflex Knee Implant, Citing Meddling by Congressmen, Former FDA Commissioner
– 32 Orthopedic and Spine Devices Receive FDA Clearance in August
– FDA Sends Johnson & Johnson Letter of Warning
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
